Physician profile
Nardos Temesgen
NPI 1508250424
$7,501.27
in general payments reported to CMS, 2019-2025
28 companies · $754 in 2025
The $754 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.43 · 2021: $436 · 2022: $3,224 · 2023: $1,189 · 2024: $1,859 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Travel and Lodging: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.68 |
| Travel and Lodging | $770.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,295.17 | 2021-2025 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Abbott Laboratories | $395.39 | 2022-2024 | Coroflow, Aveir, Cardiomems |
| Novartis Pharmaceuticals Corporation | $320.89 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $291.29 | 2023-2025 | Lifevest |
| Cardiovascular Systems INC. | $282.14 | 2021-2023 | Diamondback Coronary |
| Terumo Medical Corporation | $240.82 | 2025 | Metacross Otw, Navicross, Angio-Seal |
| Chiesi USA, INC. | $195.63 | 2021-2024 | Kengreal |
| Boston Scientific Corporation | $177.86 | 2021-2022 | |
| Abiomed | $149.77 | 2025 | |
| Novo Nordisk INC | $143.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $109.88 | 2024 | Opsumit, Uptravi |
| Atricure, INC. | $95.47 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $78.92 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $78.62 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $74.05 | 2023-2024 | Wainua |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.36 | 2023-2024 | Repatha |
| Philips North America LLC | $59.00 | 2023-2025 | Ecc Solutions, Mcot |
| Edwards Lifesciences Corporation | $57.43 | 2022 | |
| Alnylam Pharmaceuticals INC. | $51.01 | 2024-2025 | Amvuttra |
| Shockwave Medical, INC | $50.64 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Scpharmaceuticals INC. | $47.84 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $47.57 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.70 | 2023-2024 | Jardiance |
| Pfizer INC. | $41.32 | 2022-2025 | |
| Medtronic Vascular, INC. | $39.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.02 | 2025 | Cobenfy |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| Biotronik INC. | $14.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nardos Temesgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.